Second-line treatment for cancer progression, following trial participation, for patients in the rucaparib group was with programmed cell death protein-1–directed checkpoint inhibitor immunotherapy in three (25%) patients and paclitaxel in one (8%) of the 12 who had experienced a PFS event. Here, PDCD1 is linked to cancer.